1Q FY2013(Fiscal Year Ending March 31, 2014)

Financial Results Presentation
Eisai Co., Ltd.

August 1, 2013

Safe Harbor Statement

2•

Materials and information provided during this presentation may contain so-called “forwardlooking statements.” These statements are based on current expectations, forecasts andassumptions that are subject to risks and uncertainties which could cause actual outcomes andresults to differ materially from these statements.

•

Risks and uncertainties include general industry and market conditions, and general domestic
and international economic conditions such as interest rate and currency exchange fluctuations.
Risks and uncertainties particularly apply with respect to product-related forward-looking
statements. Product risks and uncertainties include, but are not limited to, technologicaladvances and patents attained by competitors; challenges inherent in new productdevelopment, including completion of clinical trials; claims and concerns about product safety
and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic
and foreign healthcare reforms; trends toward managed care and healthcare cost containment;
and governmental laws and regulations affecting domestic and foreign operations.

•Also, for products that are approved, there are manufacturing and marketing risks anduncertainties, which include, but are not limited to, inability to build production capacity to meetdemand, unavailability of raw materials, and failure to gain market acceptance.

•

The Company disclaims any intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or otherwise.

•This English presentation was translated from the original Japanese version. In the event of
any inconsistency between the statements in the two versions, the statements in the Japaneseversion shall prevail.

Focus Points of Proactive Approach for
Recovery from Bottom-out in FY2013
Focus on growth drivers
 Seek 115B yen sales and 172% YOY for next-generation six products Launch BELVIQ and Fycompa in the U.S.
 Aim for over 20% growth in China and Generic Businesses

Transformation in cost structure Concentrated investment in strategic areas and cost optimization:
22% on R&D expenses and 33% level on SG&A expenses
 Proactive financial policy  40% level on investment for growth + secure
strategic investment capacity

Forecast for FY2013 financial results
 Sales plan: 101% YOY, double-digit growth in OP and net income
Sales
578.0B yen (101% YOY) ROE
11.5%
Operating income 78.5B yen (111% YOY) EPS
186.6 yen
Net income
53.2B yen (110% YOY) Dividend 150 yen
Pharma EBIT*
206.0B yen (108% YOY)
Cash income
100.0B yen (99% YOY)
3

* Pharma EBIT: Operating Income+ R&D Expenses

1Q FY2013 Consolidated Financial Results

The first increase in revenue and gross profit since 2Q FY2010(Billion yen, %)April – June 2012
Results%

April – June 2013
Results%

YOY

Net Sales

146.9

100.0

154.2

100.0

105

Cost of Sales

43.2

29.4

46.3

30.0

107

Gross Profit

103.7

70.6

108.0

70.0

104

R&D Expenses

28.4

19.3

39.6

25.7

140

SG&A Expenses

56.2

38.3

54.2

35.1

96

Operating Income

19.1

13.0

14.2

9.2

74

Ordinary Income

17.9

12.2

12.9

8.3

72

Net Income

11.9

8.1

9.4

6.1

79

Pharma EBIT*1

47.5

32.3

53.8

34.9

113

Cash Income*2

24.3

21.9

90

*1: Pharma EBIT: Operating Income+ R&D Expenses*2: Cash income is the total amount of cash available for investments for growth, business development, dividend payment, and repayment of borrowings, etc.
Cash income: Net income + Depreciation of PP&E and Amortization of intangible assets + In-process R&D + Amortization of goodwill + Impairment loss
(including loss on devaluation of investment securities)
4 1Q FY2013 average exchange rates: U.S.$ = 98.75 yen (YOY +23.1%), Euro = 128.94 yen (YOY +25.3%), GBP = 151.59 yen (YOY +19.5%)

Sustainable Growth of Next-Generation Six
Products will Drive Recovery from Bottom-out
Total
21.3B yen
134% YOY(Billion yen)
250

25

Total
16.0B yen200
20

Next-generation
6 growth drivers
ハラヴェン
Halaven
Fycompa
Fycompa

150

15

Total
10.2B yen

ヒュミラ
Humira

100

10

リリカ
Lyrica*50
5Lunesta
ルネスタ
BELVIQBELVIQ0
2011年度1Q
1Q FY20115

2012年度1Q
1Q FY20122013年度1Q
1Q FY2013* Alliance revenueAnalysis of Attribution Factors for
Increased/ Decreased Operating Income

Operating income increased before R&D related milestone payment(Billion yen)
25

20

20.9
15

19.1
14.2

10

5

0
1Q FY2012
Operatingincome6*1: Alliance revenue*2: Proof of Concept

Rapid growth of
next-generation
six products
Halaven
Fycompa
BELVIQ
HumiraLunesta
Lyrica*1

Growing
segments
Asia Region
Generic
Business

Investment
Improved costassociatedwithstructure due to
BELVIQlaunchtransformation intolean operation
Continuous cost
optimization
including alliancecost

1Q FY2013
Increase in
1Q FY2013
R&D milestone
Operating
R&D
Operatingpayment
incomeinvestment
income(before R&D
associated*2
Quintiles POC
milestonewithachievement
payment)
progression of
BAN2401 Ph. II
initiation
projects and
E7438
Ph.
I/II initiation
othersSuccessful Start to FY2013
for Eisai Japan

Eisai Japan 1Q FY2013
Strong start toward achieving FY2013 target

Net sales achieved 102% of target(1.8B yen over)

100% YOY(Generic Business: Net sales 5.8B yen, sustained 131% growth)

Segment profit achieved 118% YOY
2 newly established hhc units based on patients’ medical consultation
MR activities in all 259 medical consultation areas are steadily ongoing
7 7

Dementia in Japan and Eisai’s Role
Proactive support with the goal ofdelivering AD treatment toapprox. 2 million untreated patientsout of approx. 3.12 million

Prevalence of dementia population aged 65 andover is 15% in Japan (2012*)
The number of patients with Alzheimer’s diseasereached approx. 3.12 million(%)

Proportion of dementia patients

90

Number of patients

80



70
60
50
40

New business structure resulted in achieving
1Q FY2013 target(18.3 billion yen net sales, representing 104% of target)

30



20
10

Launched new Dry Syrup on June 26, 2013

0

65~69

70～74 75～79 80～84 85～89 90～94

95～ (age)

The number of elderly people withdementia in Japan is estimated to beapprox. 4.62 million*
 Approx. 4 million* are estimated tohave mild cognitive impairment(MCI), which is considereda preliminary stage of dementia


Alzheimer’s disease dementia represents
67.6%* of all types of dementia(n=978: Patients with established diagnosis by a face-to-face interview
survey)82013
Launchdry syrup

Support patients’ needs
with a new way ofadministration

1999
LaunchAricept(Tablets)

2001
LaunchFine
Granules0.5%

2004
LaunchODT*Findings of a study with 9,000 people aged 65 and over conducted in 10 cities in Japan as a Science Grant Research Program
sponsored by MLHW

2007
Severe AD
Indication
10mg
Tablets2009
LaunchAricept
Oral Jelly

Continuous Commitment to Patients throughAricept in Japan
Initiation of potential patients to AD treatment
 Operate specialized activities fitted to local situations at 238 medical consultation areas, aiming for patientsto seek early medical consultation
 Enhance disease awareness activities through “e-65.net”*1 and “Dementia Forum for New Era”*2 for
consumers

Provide community support services for dementia
 Increase commitment to support community networking along with 5-Year Orange Plan*3
 Seek to establish patient support program in the community to help provide early medical consultation andproper information

Contribution to patients through Aricept
 Aim to create innovative evidence on Aricept’s contribution efficacy to help prolong the length of staying attheir own home/ healthy life-span for AD patients
 Plan to hold knowledge sharing meetings with pharmacists to help improve patients’ adherence rate

64,000 new patients started treatment with Aricept (4Q FY2012: 56,000)*4
Improved adherence rate: 4 weeks adherence: 69.8% (September 2012) to 70.6% (April 2013)*4

Solid achievement of 1Q FY2013 target through Eisai Japan’s
new business model
9*1: e-65.net: Dementia information website for consumers*4: Internal estimate*2: “Dementia Forum for New Era”: Dementia forum for consumers co-sponsored by Eisai*3: Orange Plan: Dementia support program (2013-2017) prepared by the Ministry of Health, Labor and WelfareContinuous Commitment to Patients throughHalaven in Japan

Utilization of evidence
Expand contribution to MBC*1 patients by focusing on the clinical significance of a series of clinical studies,including two large-scale clinical studies, Study 305 (EMBRACE) and 301, and Phase II study in Japan Seek contribution to MBC patients in earlier lines through discussing Halaven’s new data (potential inhibitory
effect on tumor metastasis hypotheses, QOL) presented at AACR*2 and ASCO*3

Strengthened approach to customers
 Strengthen approach to surgeons, who account for more than half of all doctors that treat breast cancer
 Respond flexibly to medical needs based on local characteristics, including hospital-clinic collaborations andhospital-hospital collaborations, under the new business model which focus on patients’ consultation behavior
and collaborations among medical institutions for cancer treatment

Creation of evidence from Japan

 Accelerate creation of evidence to seek increase in share in earlier lines of MBC treatment, including neoadjuvant treatment
 Accelerate creation of evidence as a first choice in recurrent breast cancer patients previously treated with AT*4(100 million yen)

20

Halaven sales in Japan achieved 123% YOY 10
due to the new strategy to focus on0
broad medical districts
10

Sales of Halavenin Japan

1Q FY20122012年度1Q

1Q FY20132013年度1Q*1: Metastatic breast cancer * 2: American Association for Cancer Research *3: American Society of Clinical Oncology *4: A: anthracycline , T: taxanes

Robust Launch Metrics &Early Success on BELVIQ
Toward Future Growth

Launch Summary• Continue to increase the number of TRx
with double-digit growth week over week
(excludes the week ending 7/5 for the Independence Day holiday) TRx were 2,840* in the week ending

7/19• Approx. 3,900 physicians* have written
BELVIQ prescriptions since its launch••Over 14,000 patients registered for BELVIQ patient
support program since the launch
Provide 15-day free trial voucher
and savings cards for patientswith and without commercial coverage More than 60% of initial prescriptions
are for voucher programs leading to early patient
experience and treatment for weight management•(as of 7/19)
4,000

Approx. 30% coverage of commercial lives withformulary access in ongoing contract discussions
with many major plans Seek 50% access coverage by the end of FY2013,
earlier than the original plan

Number of TRx(Weekly)
3,000

15,0002,000

10,000

1,000

IMS

5,000

Symphony Health

0

11

0
* Source: IMS

Patient Support Program
Registrations (accumulated)Public Awareness• News coverage of availability of BELVIQ reachedover 300 million people Over 100 TV segments
 Over 300 news sites picked up the press
release, reaching 74 million readers 17 million radio listeners reached through radio
news segments
 Featured on Times Square and Las Vegas
Jumbotron• Availability covered by:
The New York Times, The Wall Street Journal,
Reuters, FOX Business, Bloomberg TV, CNBC,
ABC News, etc.
• Satellite and Radio Media Tour
 Reached 2.8 million people via interviews
featuring weight management KOLs
• BELVIQ website for healthcare professionals has
experienced a higher than expected traffic Over 100,000 unique visits in first month12

CNBC: http://www.cnbc.com

Developments in Obesity Treatment

The American Medical Association
Declaration of “obesity as a disease”

The American Association of Clinical Endocrinologists
BELVIQ listed in the Guidelines as a weight management option
for overweight/obese patients

The U.S. Department of Veterans Affairs
Access for BELVIQ via VA Criteria for Use Program

The U.S. Congress
Treat and Reduce Obesity Act: Introduced by Members of Congress toeliminate exclusion rule in Medicare Part D
13

New Clinical Data Presented at
American Diabetes Association in June

Efficacy for weight loss confirmed by an additional analysis
Presented new clinical data on patients who achieved approx. 5% weight loss
at Week 12 with BELVIQ (responders: patients with 5% weight loss at Week 12)
Demonstrated BELVIQ’s weight loss effect at Week 52, compared to placebo,
given percent change in body weight by Week 12 responder status
in patients without DM*1/ with T2DM*2
Eisai Product Theater

In this post-hoc subgroup analysis, these data demonstrated drug efficacy of approx. 10% at
Week 52 for patients without diabetes*3
Patients without DM

Patients with T2DM

Eisai’s exhibit
booth

Ratio of responders(calculated from the above chart)

BELVIQ: 49.3% vs. placebo: 22.6%
The percentage of patients treated with BELVIQ
who achieved ≥5% weight loss at W52: 86%*1 DM: Diabetes Mellitus *2 T2DM: Type 2 Diabetes Mellitus*3 Adapted from poster presented by Steven R. Smith et al at the 73rd

14

Annual Meeting of the American Diabetes Association; June 21-25, 2013;
Chicago, IL.

Ratio of responders
BELVIQ: 35.9% vs. placebo: 11.5%
The percentage of patients treated with BELVIQ
who achieved ≥5% weight loss at W52: 71%

Response to therapy should be evaluated by Week 12. If a patient has not lost at least 5% ofbaseline body weight, discontinue BELVIQ as it is unlikely that the patient will achieve andsustain clinically meaningful weight loss with continued treatment

China to Drive Growth
1Q FY2013 Sales: 7.0 billion yen 137% YOY(100 million yen)(100 million yen)

Aricept

Methycobal

Rapid aging of society
・Established 128 memory clinics

Continuous growth of top sales
product in China
158%
YOY

Memory Clinic established in a hospital in China

・Communicating the importance ofearly diagnosis and treatment
through disease awarenessactivities

9.9
6.3

1Q FY2012

1Q FY2013• Strengthen production capability by
establishing a new parenteral
formulation facility in Suzhou Plant(To be completed in 1H FY2014)• Create innovative
evidence in China forfurther contributions
to patients

Rendering of parenteral formulation
facility in Suzhou Plant

135%
YOY
30.1
22.2

1Q FY2012

1Q FY2013(100 million yen)

In-house establishedproducts

Pariet• Enhance maximization of productvalue since start of independent
promotion• Provide support for improvement
in endoscopic technology in
China

162%
YOY
5.4
3.4

1Q FY2012

15

1Q FY2013

Five products outperformed
market growth since launch

151%
YOY

Merislon, Myonal, Glakay, Selbex,
Neuquinon
1Q FY2012

1Q FY2013

Proactive Business Operationsin Asia and Emerging Countries
CanadaExpanding product line from 4 launched
products

ＲｕｓｓｉａEstablished sales
subsidiary in April 2013

・ Fycompa: approved in April and launched in July
・ BELVIQ: application submitted in June

・ Halaven: to belaunched in September
・ Zonegran, Exalief*:
to be launched in
FY2013Mexico• Applications for 7 products including Halaven,
Fycompa, and BELVIQ are under regulatory
review for approval

Brazil* Product name of Zebinix in Russia

In the final stage of business
commencement

・ Halaven: received approval in May,

Further contribution to patients in Asia Region

preparing to launch within FY2013• Gliadel: application filed<Robust growth of launched products>
China

Hong
Kong

Taiwan

South
Korea

ThailandIndonesia

Malaysia

Singapore

Philippines

India

10 subsi
diaries
total

137

170

137

139

135

138

138

134

145

245

139

(yen base)

1Q 2013YOY (%)In the final stage of business
commencement<New products launch in FY2013>
Halaven16

Aricept 23mg

Launched

Launch plan in FY2013

Singapore, South Korea,
Hong Kong, Thailand, Philippines

Indonesia, India, Malaysia
South Korea, Hong Kong, Thailand, India

Contribution to Patients Treated with Halaventhrough Tiered Pricing
Hong Kong Treatment cycle

Increase patient access throughIncomelevel

tiered pricing based on income level

High

SchemeReimbursement*3

Low 2 vial/ cycle free

SchemeTreatment cycle
1 cycle2 cycles3 cycles4 cyclesIncomelevel

Scheme*1High

Reimbursement

Free

Free

Free

Free
Low

High Out-of-pocket *2 Out-of-pocket Out-of-pocket Out-of-pocket Out-of-pocket

1 cycle free

Low

17

Out-of-pocket Out-of-pocket Out-of-pocketFree

2 cycles free

Out-of-pocket Out-of-pocket

Free

Free

3 cycles free

Out-of-pocket

Free

Free

4 cycles free

3 cycles4 cyclesOut-of-pocket Out-of-pocket Out-of-pocket Out-of-pocket
50% Reduced 50% Reduced 50% Reduced 50% Reduced
burdenburdenburdenburden1 cycle2 cycles3 cycles4 cyclesOut-of-pocket

Out-of-pocket

Out-of-pocket

Out-of-pocket

1 vial/cycle free

25% Reduced
burden25% Reduced
burden25% Reduced
burden25% Reduced
burden4 cycles free

Free

Free

Free

Free

1 cycle2 cycles3 cycles4 cycles*3Out-of-pocket

Out-of-pocket

Out-of-pocket

Out-of-pocket

Military/
Public official

ReducedburdenReducedburdenReducedburdenReducedburden1 cycle free

Out-of-pocket

Out-of-pocket

Out-of-pocketFree

4 cycles free

Free

Free

Free

Free

*3

Reimbursement

2 cyclesPhilippines

India
Incomelevel

1 cycle

Free

Free
Free

Free

Thailand
Income
level

High

Free

*1 Public insurance for national and local governmental officers; less than 5% of
total population of India are insured*2 Wealthy patients who are not insured by a public health insurance*3 Subject to private health insurance

Low

SchemeReimbursement

Next-Generation Product Creation
Product creation by leveraging partnerships

Lenvatinib

Strategic partnership with Quintiles
Achieved POC* for melanoma

BAN2401

Product creation of next-generation investigational
Alzheimer’s disease treatment with BioArctic
Initiated POC study utilizing an adaptive design with novel
score

E7438

Strategic partnership with Epizyme
Initiated the first Phase I/II study for EZH2 inhibitor

Indicate important progress in
AD and oncology area
18

* Proof of Concept

The agents listed on the slide are investigational

Next-Generation Product Creation
Steady progress in investigational lenvatinib through strategic partnership
In-house developed, oral, molecular-targeting agent with a unique inhibitory
profile of receptor tyrosine kinases

Lenvatinib

In-house POC (thyroid cancer, hepatocellular carcinoma, and endometrial cancer) andadditional important POC achieved through strategic partnership with Quintiles

Phase II study results for melanoma*1 (presented at ASCO*2)
Combination of lenvatinib and dacarbazine
demonstrated a statistically significant 2.7-foldincrease in PFS*3 versus dacarbazine alone

Stratified analysis of wild-type BRAF demonstrated
a statistically significant 3.9-fold increase in PFSMedian PFSMedian PFS

Substantial unmet medical needs exist for BRAF wild-typemelanoma, which accounts for about half of all melanoma,
because standard therapy is not established

P=0.0033

lenvatinib + dacarbazine 23.9 weeks
dacarbazine
6.1 weekslenvatinib + dacarbazine 19.1 weeks
dacarbazine
7.0 weekslenvatinib +dacarbazine (n=20)

lenvatinib +dacarbazine (n=40)
dacarbazine(n=38)

P=0.0306

dacarbazine(n=23)

 Thyroid cancer

Planning simultaneous submissions in the U.S., Europe and Japan in FY2013
Received orphan drug designation in the U.S., Europe, and Japan
 Hepatocellular Carcinoma (HCC)
Initiated Phase III study and is ongoing Non Small-Cell Lung Cancer (NSCLC) (RET translocation)
Phase II study is ongoing*1 The most common Grade 3/4 adverse events in the lenvatinib + dacarbazine arm were hypertension (26%) and neutropenia (10%)

19 *2 ASCO: American Society of Clinical Oncology in June 2013 *3 PFS: Progression-free survival

Next-Generation Product Creation
Next-generation Alzheimer’s disease treatments:
investigational BAN2401/E2609

BAN2401 A novel anti A-beta protofibrils monoclonal antibody that is being developed as a potential
next-generation therapeutic treatment for Alzheimer’s disease through partnership with BioArctic

Phase II study for A-beta positive MCI*1 patients and mild AD patients is ongoing; endpoint is an
in-house developed composite score*2 with enhanced sensitivity to clinical course andtreatment effect for early AD patients
64 patients enrolled
Image of Bayesian Adaptive Design
Placebo arm
Active drug arm 1
Active drug arm 2
Active drug arm 3
Active drug arm 4
A-beta positive patientsdiagnosed by imaging
participate in the study

InterimAnalysisInterimAnalysisInterimInterim Interim
Analysis Analysis Analysis

InterimInterimAnalysis Analysis

Evaluate composite score as a primary endpoint at each interim analysis
The study will be finished when a prospect for significant difference is observed
compared with placebo ⇒ Aiming for early POC achievement
More patients are preferentially allocated to an arm with higher efficacy and safety

E2609
•
•

A next-generation investigational compound for Alzheimer’s disease developed in-house being
explored for symptomatic improvement and disease modifying therapy by BACE inhibitory activity

Reduction in A-beta levels in blood/CSF*3 was confirmed in Phase I single and multiple dosestudies in healthy adults
Preparing for Phase II study under strategy similar to BAN2401

20 *1 Mild cognitive impairment *2: Composite score: composed of ADAS-Cog, MMSE and CDR *3 CSF: Cerebrospinal fluidNext-Generation Product Creation

Steady progress on investigational E7438 in oncology pipeline
through strategic partnership

E7438 Investigational anticancer agent targeting histone methyltransferase
The world’s first Phase I/II
clinical study of an EZH2
inhibitor initiatedInitiated development of companion
diagnostics (CoDx), focusing on
discovering EZH2 Y641 mutation

Partnership with
EpizymePartnership with Roche Molecular
Systems

Aiming for effective implementation of Phase II study through identification ofpatients most likely to benefit from E7438 with data from Phase I study and
CoDx for detection of EZH2 mutation
Epigenetic transcriptional repression induced by EZH2
Y641 mutation induces histone H3 methylationand controls the expression of tumor suppressor
gene

EZH2 is believed to be a critical player
in maintaining genetic characteristic ofcancer stem cells
A novel mechanism fortargeting cancer stem cells

21Reference

22Sales by Segment(Billion yen, %)April – June
2013
Sales
%
YOY

April – June
2012
Sales
%

Japan*1
Americas*2

81.3

55.3

81.0

52.5

Japan

100

52%

55%

[$ million]

38.6
[481]

26.3

Asia*3

9.6

6.5

41.3
[418]

26.8

13.4

8.7

52%

107
[87]

Americas

Asia

139
EMEA

EMEA*4OTC (Japan)

6.9
4.1

4.7
2.8

7.9
4.7

5.1
3.0

115
113

27%

26%

ReportingSegment Total

140.6

95.7

148.2

96.1

105

Others

6.3

4.3

6.0

3.9

96

7%

9%

105

5%
7%

5%
7%

1Q FY2012

1Q FY2013

Consolidated
Sales

146.9

100.0

154.2

100.0

[ ] based on local currency
Pharmaceutical Businesses of Japan, Americas, Asia, and EMEA
Segment profit from Americas pharmaceutical business in local currency was calculated
based on average exchange rate

23

*1 Prescriptions, generic drugs, and diagnostics*2 North, Central, and South America*3 China, South Korea, Taiwan, Hong Kong, India ,and ASEAN*4 Europe, Middle East, Africa, and Oceania

24%

10%
7%
7%
Plan
"HAYABUSA"
FY2015OTC(Japan)
and others

Profit by Segment(Billion yen, %)April – June 2012
Results

April – June 2013
% on
Sales

%

Results%% on Sales

YOY

Change fromprevious year

Japan

36.2

72.8

44.6

42.9

76.1

53.0

118

6.7

Americas[$ million]

8.1
[101]

16.3

21.0

6.0
[61]

10.7

14.6

74
[60]

(2.1)
[(40)]

Asia

1.8

3.7

18.9

3.0

5.3

22.5

166

1.2

EMEA

0.4

0.8

5.9

0.7

1.2

8.4

164

0.3

OTC (Japan)

0.3

0.6

7.5

0.5

0.9

11.0

164

0.2

Reporting Segment
Total

46.9

94.2

33.4

53.1

94.2

35.8

113

6.2

Others

2.9

5.8

45.3

3.3

5.8

54.2

114

0.4

9.2

74

(5.0)

R&D expenses & Nonallocated SG&A expenses(30.6)

Consolidated
Operating Profit

19.1(42.2)
13.0

14.2

Pharmaceutical Businesses of Japan, Americas, Asia, and EMEA
Segment profit from Americas pharmaceutical business in local currency was calculated based on average exchange rate24

[ ] based on local currencyPerformance of Japan Pharmaceuticals Business(Billion yen, %)April – June 2012
Results

25

April – June 2013%

Results

%

YOY

Sales

81.3

100.0

81.0

100.0

100

Prescriptions

75.5

92.9

73.8

91.1

98

Aricept

21.7

26.7

18.3

22.6

84

Pariet

13.1

16.1

12.8

15.8

98

HUMIRA

5.8

7.1

6.9

8.6

120

Methycobal

6.8

8.4

6.7

8.3

98

Actonel

2.4

3.0

2.2

2.7

89

Generic drugs

4.4

5.4

5.8

7.1

131

Diagnostics

1.4

1.7

1.4

1.7

102

Segment Profit

36.2

44.6

42.9

53.0

118

Performance of Americas Pharmaceuticals Business<Americas >(Billion yen, %)April – June 2012
Results

26

April – June 2013%

Results

%

YOY

Sales

38.6

100.0

41.3

100.0

107

Aricept

2.4

6.2

1.5

3.7

65

AcipHex

13.2

34.1

15.5

37.5

118

Halaven

3.1

8.1

3.3

7.9

105

Aloxi

9.5

24.6

10.3

25.0

109

Dacogen

4.4

11.5

5.7

13.9

130

Total MGI

14.5

37.6

16.4

39.7

113

Fragmin

2.9

7.4

1.8

4.3

62

Total oncology-related products

21.2

55.0

21.5

52.0

101

Segment Profit

8.1

21.0

6.0

14.6

74

Performance of U.S. Pharmaceuticals Business<U.S. >($ million, %)April – June 2012
Results%

Results

%

YOY

Sales

481

100.0

417

100.0

87

Aricept

30

6.2

16*

3.8

53

AcipHex

164

34.2

157

37.7

96

Halaven

39

8.1

32

7.8

84

Aloxi

119

24.7

105

25.1

88

Dacogen

55

11.5

58

13.9

105

Total MGI

181

37.6

166

39.8

92

Fragmin

36

7.5

18

4.4

51

265

55.1

217

52.1

82

Total oncology-related products*including $11M from Aricept 23mg sales

27

April – June 2013

Performance of Asia Pharmaceuticals Business<Asia>(Billion yen, %)April – June 2012
Results

April – June 2013%

Results%

YOY

Pariet

9.6
2.0
1.1

100.0
20.7
11.5

13.4
2.9
1.4

100.0
22.0
10.7

139 [111]
147 [117]
129 [103]

Methycobal

2.5

26.0

3.6

26.8

143 [114]

HUMIRA

1.1

11.0

1.6

12.1

153 [123]

0.9

9.7

1.2

9.0

130 [103]

1.8

18.9

3.0

22.5

166 [124]

Sales
Aricept

Stronger Neo-Minophagen C/
Glycyron Tablets
Segment Profit[ ] based on local currency(MM RMB, ％)<China>April – June 2012
Results

Sales
Methycobal
Stronger Neo-Minophagen C/
Glycyron Tablets

Aricept
Pariet28%

April – June 2013
Results

%

YOY

404
175

100.0
43.3

438

100.0

109

188

42.8

107

72

17.8

74

16.9

103

49
26

12.2
6.5

62

14.1

125

34

7.7

128

Performance of EMEA and Consumer Healthcare Business(OTC and other businesses)＜EMEA＞(Billion yen, %)April – June 2012
Results

April – June 2013%

Results

%

YOY

Sales
Halaven
Zonegran

6.9
1.0
1.1

100.0
15.1
15.8

7.9
2.0
1.6

100.0
25.8
19.7

115 [92]
195 [157]
143 [115]

Aricept

1.2

16.7

0.4

5.5

38 [30]Pariet

1.2

17.0

0.2

2.1

14 [12]

0.7

8.8

0.7

8.4

Fycompa
Segment Profit

0.4

5.9

164 [52][ ] based on local currency＜Consumer Healthcare Business- Japan＞(Billion yen, %)April – June 2012
Results

April – June 2013%

Results

%

YOY

Sales

4.1

100.0

4.7

100.0

113

Chocola BB Group

2.4

57.9

2.9

61.3

119

Segment Profit

0.3

7.5

0.5

11.0

164

[ ] based on local currency
29

Forecast for FY2013 Consolidated Financial Results
FY2012
Results%

Forecast(Billion yen, %)

%

YOY

573.7

100.0

578.0

100.0

101

174.1

30.3

180.5

31.2

104

Gross Profit

399.6

69.7

397.5

68.8

99

R&D Expenses

120.4

21.0

127.5

22.1

106

SG&A Expenses

208.7

36.4

191.5

33.1

92

Operating Income

70.5

12.3

78.5

13.6

111

Ordinary Income

65.6

11.4

74.9

13.0

114

Net Income

48.3

8.4

53.2

9.2

110

Pharma EBIT*1

190.8

33.3

206.0

35.6

108

Sales
Cost of Sales

30

FY2013

EPS (yen)

169.4

186.6

ROE (%)

10.9

11.5

Equity Spread (%)*2

2.9

3.5

DOE (%)

9.6

9.2

Cash Income*3

100.7

100.0

Dividends (yen)

150

150

*1: Pharma EBIT: Operating Income+ R&D Expenses*2: Equity Spread = ROE – Cost of Equity (%)*3: Cash income is the total amount of cash available for investments for growth, business development, dividend payment, and repayment of borrowings, etc.
Cash income: Net income + Depreciation of PP&E and Amortization of intangible assets + In-process R&D + Amortization of goodwill + Impairment loss
(including loss on devaluation of investment securities)
FY2012 average exchange rates: U.S. $ = 83.10 yen, Euro = 107.14 yen, GBP = 131.13 yen FY2013 estimated exchange rates: U.S. $ = 95 yen, Euro = 125 yen, GBP = 145 yen